These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 26126902)

  • 1. Nanobodies and their Use in GPCR Drug Discovery.
    Cromie KD; Van Heeke G; Boutton C
    Curr Top Med Chem; 2015; 15(24):2543-57. PubMed ID: 26126902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanobodies detecting and modulating GPCRs outside in and inside out.
    Heukers R; De Groof TWM; Smit MJ
    Curr Opin Cell Biol; 2019 Apr; 57():115-122. PubMed ID: 30849632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GPCR-targeting nanobodies: attractive research tools, diagnostics, and therapeutics.
    Mujić-Delić A; de Wit RH; Verkaar F; Smit MJ
    Trends Pharmacol Sci; 2014 May; 35(5):247-55. PubMed ID: 24690241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanobodies: New avenues for imaging, stabilizing and modulating GPCRs.
    De Groof TWM; Bobkov V; Heukers R; Smit MJ
    Mol Cell Endocrinol; 2019 Mar; 484():15-24. PubMed ID: 30690070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of nanobodies for therapeutic applications.
    Van Bockstaele F; Holz JB; Revets H
    Curr Opin Investig Drugs; 2009 Nov; 10(11):1212-24. PubMed ID: 19876789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of Nanobodies on G Protein-Coupled Receptor Structural Biology and Their Potential as Therapeutic Agents.
    Salom D; Wu A; Liu CC; Palczewski K
    Mol Pharmacol; 2024 Sep; 106(4):155-163. PubMed ID: 39107078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis for selectivity and antagonism in extracellular GPCR-nanobodies.
    Schlimgen RR; Peterson FC; Heukers R; Smit MJ; McCorvy JD; Volkman BF
    Nat Commun; 2024 May; 15(1):4611. PubMed ID: 38816420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation and characterization of nanobodies targeting GPCR.
    Zhang S; Fan Z; Liu J
    Biophys Rep; 2024 Feb; 10(1):22-30. PubMed ID: 38737476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure and function of G protein-coupled receptor oligomers: implications for drug discovery.
    Schonenbach NS; Hussain S; O'Malley MA
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2015; 7(3):408-27. PubMed ID: 25521522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences between G-Protein-Stabilized Agonist-GPCR Complexes and their Nanobody-Stabilized Equivalents.
    Saleh N; Ibrahim P; Clark T
    Angew Chem Int Ed Engl; 2017 Jul; 56(31):9008-9012. PubMed ID: 28481446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cryo-EM advances in GPCR structure determination.
    Shihoya W; Iwama A; Sano FK; Nureki O
    J Biochem; 2024 Jul; 176(1):1-10. PubMed ID: 38498911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanobodies as Probes and Modulators of Cardiovascular G Protein-Coupled Receptors.
    Wingler LM; Feld AP
    J Cardiovasc Pharmacol; 2022 Sep; 80(3):342-353. PubMed ID: 34840268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanobodies as sensors of GPCR activation and signaling.
    El Daibani A; Che T
    Methods Cell Biol; 2021; 166():161-177. PubMed ID: 34752331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging Approaches to GPCR Ligand Screening for Drug Discovery.
    Kumari P; Ghosh E; Shukla AK
    Trends Mol Med; 2015 Nov; 21(11):687-701. PubMed ID: 26481827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yeast surface display platform for rapid discovery of conformationally selective nanobodies.
    McMahon C; Baier AS; Pascolutti R; Wegrecki M; Zheng S; Ong JX; Erlandson SC; Hilger D; Rasmussen SGF; Ring AM; Manglik A; Kruse AC
    Nat Struct Mol Biol; 2018 Mar; 25(3):289-296. PubMed ID: 29434346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanobodies: The Future of Antibody-Based Immune Therapeutics.
    Bathula NV; Bommadevara H; Hayes JM
    Cancer Biother Radiopharm; 2021 Mar; 36(2):109-122. PubMed ID: 32936001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. G-protein-coupled receptor-focused drug discovery using a target class platform approach.
    Heilker R; Wolff M; Tautermann CS; Bieler M
    Drug Discov Today; 2009 Mar; 14(5-6):231-40. PubMed ID: 19121411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accelerating GPCR Drug Discovery With Conformation-Stabilizing VHHs.
    Laeremans T; Sands ZA; Claes P; De Blieck A; De Cesco S; Triest S; Busch A; Felix D; Kumar A; Jaakola VP; Menet C
    Front Mol Biosci; 2022; 9():863099. PubMed ID: 35677880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanobodies to Study G Protein-Coupled Receptor Structure and Function.
    Manglik A; Kobilka BK; Steyaert J
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():19-37. PubMed ID: 27959623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SNAP-Tagged Nanobodies Enable Reversible Optical Control of a G Protein-Coupled Receptor via a Remotely Tethered Photoswitchable Ligand.
    Farrants H; Gutzeit VA; Acosta-Ruiz A; Trauner D; Johnsson K; Levitz J; Broichhagen J
    ACS Chem Biol; 2018 Sep; 13(9):2682-2688. PubMed ID: 30141622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.